



Angion  
Biomedica Corp.  
51 Charles Lindbergh Boulevard  
Uniondale, NY 11553  
Phone: 516-326-1200  
Fax: 516-307-1659  
[www.angion.com](http://www.angion.com)

## **Angion Biomedica Corp. Expands Personnel with New Director of Discovery and Medicinal Chemistry, and Director of Clinical Operations**

Uniondale, NY – September 7, 2017 – Angion Biomedica Corp., a biopharmaceutical company that discovers and develops novel therapeutic agents to treat patients who experience acute and chronic organ disorders and diseases, today announced the filling of the positions of Director of Discovery and Medicinal Chemistry, and a Director of Clinical Operations, in order to expand its capabilities in these areas.

Dr. An-Hu Li joins us as Director, Discovery and Medicinal Chemistry. He received his Ph.D. from the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China, was a Visiting Fellow at the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, and as a Postdoctoral Fellow at Harvard University under Nobel Laureate Prof. E.J. Corey. Subsequently he had positions at OSI Pharmaceuticals and Astellas Pharma (after their acquisition of OSI) in medicinal chemistry. Dr. Li brings world-class experience with small molecule modulators of biological targets for use in disease. Dr. Li has several patents and publications to his name, and in his prior career brought more than 5 novel compounds from discovery to clinical development.

Angion's Director of Clinical Operations, Patrick Simms, brings over 20 years of protocol to publication experience with clinical trials and regulatory affairs. He has managed complex clinical trial operations including Phase 1 proof of concept and characterization studies, Phase 2 trials and a number of global Phase 3 clinical trials. Mr. Simms has overseen development and approval of numerous drug products in his career, as well as CMC operations, at Biodel Inc., MannKind Corporation, ChemWerth Inc. and Arco Research. He will assume responsibility for Angion's ongoing clinical studies, the Phase 3 "GIFT" study on BB3 in patients receiving a cadaveric renal transplant to reduce the severity of delayed graft function, and the Phase 2 "GUARD" clinical trial in patients at risk for acute kidney injury (AKI) after undergoing cardiothoracic surgery under cardiopulmonary bypass. BB3, a small molecule that mimics the activity of hepatocyte growth factor (HGF), has demonstrated

therapeutic effects in preclinical models of AKI and in a Phase 2 clinical study in cadaveric renal transplant.

“We are extremely pleased to announce bringing An-Hu and Patrick on board to enhance our capabilities in the discovery and clinical operations areas,” said Itzhak D. Goldberg, MD, FACR, President and CEO of Angion. “Our clinical trials represent the culmination of significant work translating our discovery efforts into a drug candidate with tremendous therapeutic potential, and we have several new discovery programs that will add to our clinical pipeline in the very near future. These recruits complement our outstanding staff in these areas and will each assure that the discovery and development capabilities of Angion are exceptional.”

**About Angion Biomedica Corp.**

Angion Biomedica Corp. is a biopharmaceutical company established in 1998 to discover and develop novel therapeutic agents to treat patients who experience acute and chronic organ disorders and diseases. Our programs are currently focused on renal transplantation, acute kidney injury and chronic kidney disease. Angion retains worldwide rights to BB3. For further information, please visit [www.angion.com](http://www.angion.com), or contact us at [mail@angion.com](mailto:mail@angion.com).

Media Contact: Joanne Bazilio-Johnson, (516) 326-1200 ext. 200, [jjohnson@angion.com](mailto:jjohnson@angion.com)